Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients

medicalxpress.com October 5, 2016

All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of Texas MD Anderson Cancer Center.

cancer chemotherapy oncology study tumors ultrasound

AKI Risk Factors in ICU Patients Using Colistin

AKI Risk Factors in ICU Patients Using Colistin

Clinical Outcomes in Critically Ill COVID-19 Unvaccinated Patients Admitted to the ICU

Clinical Outcomes in Critically Ill COVID-19 Unvaccinated Patients Admitted to the ICU

Haloperidol vs. Placebo in ICU Patients with Delirium

Haloperidol vs. Placebo in ICU Patients with Delirium

Critical Hypertension in Trauma Patients Following Prehospital Emergency Anesthesia

Critical Hypertension in Trauma Patients Following Prehospital Emergency Anesthesia

Also Human: The Inner Lives of Doctors

How Artificial Intelligence Can Make Healthcare Human Again

Fleisher & Ludwig’s Textbook of Pediatric Emergency Medicine

Year of the Nurse: A 2020 Covid-19 Pandemic Memoir

Endoscopic Cardiac Surgery: Tips, Tricks and Traps

Seven Signs of Life: Stories from an Intensive Care Doctor

Trauma Room Two

Sepsis Management: PIRO and MODS

Extracorporeal Life Support for Adults

COVID-19 Airway Management and Ventilation Strategy for Critically Ill Older Patients

Critical Care: A New Nurse Faces Death, Life, and Everything in Between